RMD — what changed in the latest 10-Q
A section-by-section comparison of RMD's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-10-30 vs the prior 10-Q · 2026-05-01
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +52 | −74 | ~14 | 18 |
| Market risk (Item 3) | Text added/removed | +10 | −7 | ~13 | 18 |
| Controls & procedures | Text added/removed | +9 | −7 | ~5 | 15 |
| Legal proceedings | Text added/removed | +9 | −7 | ~4 | 13 |
| Risk factors | Some risk factors updated | +9 | −7 | ~3 | 12 |
| Other information | Text added/removed | +3 | −5 | ~1 | 11 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-10-30
We are a global leader in digital health and cloud-connected medical devices. We design innovative technology with the intention to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software …
On September 1, 2026, we completed the previously announced sale of our MatrixCare business. The transaction was undertaken as part of our portfolio optimization strategy to increase focus on our core growth areas of sleep, breathing, and connected home-based healthcare. The transaction does not rep…
During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles in our condensed consolidated statements of operations. Restructuring expenses, which were previously presented as a separate line item within operating expens…
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Net revenue for the three months ended September 30, 2026 was $1.4 billion, an increase of 6% compared to the three months ended September 30, 2025. Gross margin was 61.5% for the three months ended September 30, 2026 compared to 61.2% for the three months ended September 30, 2025. Diluted earnings …
Text removed vs the prior filing · source: 10-Q · 2026-05-01
We are a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing, or SDB, chronic obstructive pulmonary disease, neuromuscular dise…
Net revenue for the three months ended March 31, 2026 was $1.4 billion, an increase of 11% compared to the three months ended March 31, 2025. Gross margin was 62.2% for the three months ended March 31, 2026 compared to 59.3% for the three months ended March 31, 2025. Diluted earnings per share was $…
At March 31, 2026, our cash and cash equivalents totaled $1.7 billion, our total assets were $8.8 billion and our stockholders’ equity was $6.5 billion.
Three Months Ended March 31, 2026 Compared to the Three Months Ended March 31, 2025
Net revenue for the three months ended March 31, 2026 increased to $1,431.4 million from $1,291.7 million for the three months ended March 31, 2025, an increase of $139.7 million or 11% (an 8% increase on a constant currency basis). The following table summarizes our net revenue disaggregated by seg…
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-10-30
current levels of gross margin and operating expenses as a percentage of net revenue if we are unable to offset such higher costs through price increases.
Total Number of Shares Purchased as Part of Publicly Announced Programs(2)
Maximum Number of Shares that May Yet Be Purchased Under the Program
1.No shares during the period were repurchased other than pursuant to a publicly announced plan or program.
2.Represents the aggregate number of shares purchased under our 2014 Program, under which 20.0 million shares have been approved for repurchase.
Text removed vs the prior filing · source: 10-Q · 2026-05-01
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share (USD)Total Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Program
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in neg…
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-10-30
Total Number of Shares Purchased as Part of Publicly Announced Programs(2)
Maximum Number of Shares that May Yet Be Purchased Under the Program
1.No shares during the period were repurchased other than pursuant to a publicly announced plan or program.
2.Represents the aggregate number of shares purchased under our 2014 Program, under which 20.0 million shares have been approved for repurchase.
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negot…
Text removed vs the prior filing · source: 10-Q · 2026-05-01
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share (USD)Total Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Program
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in neg…
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-10-30
Total Number of Shares Purchased as Part of Publicly Announced Programs(2)
Maximum Number of Shares that May Yet Be Purchased Under the Program
1.No shares during the period were repurchased other than pursuant to a publicly announced plan or program.
2.Represents the aggregate number of shares purchased under our 2014 Program, under which 20.0 million shares have been approved for repurchase.
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negot…
Text removed vs the prior filing · source: 10-Q · 2026-05-01
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share (USD)Total Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Program
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in neg…
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-10-30
Total Number of Shares Purchased as Part of Publicly Announced Programs(2)
Maximum Number of Shares that May Yet Be Purchased Under the Program
1.No shares during the period were repurchased other than pursuant to a publicly announced plan or program.
2.Represents the aggregate number of shares purchased under our 2014 Program, under which 20.0 million shares have been approved for repurchase.
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negot…
Text removed vs the prior filing · source: 10-Q · 2026-05-01
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share (USD)Total Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Program
On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in neg…
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
Other information
Text added vs the prior filing · source: 10-Q · 2026-10-30
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
Transition Agreement with Brett Sandercock dated May 6, 2026.
Text removed vs the prior filing · source: 10-Q · 2026-05-01
Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In…
amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, with…
The following table describes any contracts, instructions or written plans for the sale or purchase of the Company’s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarte…
During the quarterly period ended March 31, 2026, none of our directors or executive officers terminated a Rule 10b5-1 trading arrangement or adopted or terminated a non-Rule 10b5-1 trading arrangement (each term as defined in Item 408 of Regulation S-K).
Employment Agreement with Aaron Bloomer dated April 24, 2026
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice